Quantcast

Latest Treatment of schizophrenia Stories

2009-06-10 17:32:00

WILMINGTON, Del., June 10 /PRNewswire/ -- Today, the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee conducted a review of the efficacy and safety of supplemental new drug applications (sNDAs) for SEROQUEL (quetiapine fumarate) tablets proposed for the acute treatment of schizophrenia in adolescents (13-17 years of age), and the acute treatment of bipolar mania in children and adolescents (10-17 years of age). The Advisory Committee voted as follows:...

2009-06-10 17:30:00

ADELPHI, Md., June 10 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted that Zyprexa(R) (olanzapine), an atypical antipsychotic, is effective and acceptably safe for the acute treatment of schizophrenia or manic or mixed episodes associated with bipolar I disorder in adolescents aged 13-17 years old. The panel supported the FDA and Lilly's position that if Zyprexa is approved for the two indications, prescribers...

2009-06-09 12:59:41

 Researchers have been seeking a safe and effective way to treat cognitive impairments associated with schizophrenia by enhancing N-methyl-D-aspartate (NMDA) glutamate receptors. Functional deficits in NMDA receptors may contribute to the underlying neurobiology of this disorder. The first generation of studies trying to stimulate NMDA receptors administered large amounts of substances, like glycine or D-serine, which indirectly enhance NMDA receptor function. While there were some...

2009-05-19 13:56:00

SAN FRANCISCO, May 19 /PRNewswire/ -- New data demonstrate that maintenance therapy with RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Treatment (RLAT) significantly delayed the time to relapse compared to placebo in patients with Bipolar I Disorder. Results of the study were presented this week at a major medical meeting. Bipolar Disorder is a brain disorder that causes unusual shifts in a person's mood, energy and ability to function. It is often characterized by debilitating mood...

2009-05-19 06:57:00

SAN FRANCISCO, May 19 /PRNewswire/ -- Schizophrenia is one of the most disabling diseases,(1) and frequent relapses and rehospitalization as a result of the disease place enormous burdens on patients, caregivers and society.(2) According to two new studies, the use of RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Treatment (RLAT) may improve clinical and functional outcomes and reduce rates of rehospitalization among patients with schizophrenia. Results of the studies were presented this...

2009-05-18 12:30:00

Three-year data show olanzapine LAI safety findings consistent with oral olanzapine except for injection-related events INDIANAPOLIS, May 18 /PRNewswire-FirstCall/ -- Eli Lilly and Company presented today data on the short- and long-term efficacy and safety of olanzapine long-acting injection (LAI) in the treatment of adults with schizophrenia or schizoaffective disorder. Olanzapine LAI is an investigational formulation that combines the atypical antipsychotic Zyprexa(R) (olanzapine) with...

2009-05-18 07:00:00

RISPERDAL(R) CONSTA(R) is the First and Only Long-Acting Antipsychotic Therapy Available for Bipolar I Disorder TITUSVILLE, N.J., May 18 /PRNewswire/ -- Janssen(R), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the Supplemental New Drug Applications (sNDAs) for the use of RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Treatment as both monotherapy and adjunctive therapy to lithium or valproate in the...

2009-05-14 13:52:00

ROCKVILLE, Md., May 14 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that it will present posters on its newly approved atypical antipsychotic, Fanapt(TM) (iloperidone), at the 162nd American Psychiatric Association (APA) annual meeting in San Francisco, California. Fanapt(TM) is indicated for the acute treatment of schizophrenia in adults. Vanda will also present two posters on tasimelteon at APA. Tasimelteon is an investigational compound in...

2009-05-14 09:49:51

Insight into early problems may aid understanding of disease development, diagnosis and treatment WASHINGTON "” Significant and widespread cognitive problems appear to exist in schizophrenia in its earliest phase, making it very hard for people with the disorder to work, study or be social, according to a new study published by the American Psychological Association. Understanding the early and central role of cognitive problems may help clinicians to more accurately diagnose incipient...

2009-04-08 18:14:00

WILMINGTON, Del., April 8 /PRNewswire-FirstCall/ -- Today, the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) conducted a review of the safety and efficacy of supplemental new drug applications (sNDA) for SEROQUEL XR (quetiapine fumarate) extended-release tablets proposed for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD). The Advisory Committee concluded: SEROQUEL XR was shown to be effective in MDD as...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related